NightBalance closes €12.5 million Series B financing to expand internationally with its sleep apnea device

0
312

NightBalance, a leading innovator of obstructive sleep apnea (OSA) technology, today announced the completion of a €12.5 million Series B financing round led by INKEF Capital and Gilde Healthcare Partners. Existing investors Thuja Capital, Health Innovation Fund, and Van Herk Ventures also participated.

Sleep apnea is a disorder in which you have one or more pauses in breathing or shallow breaths while you sleep. This is bad for your health and sleep quality.

Founded in 2009, NightBalance developed and markets the Sleep Position Trainer, a proprietary, highly advanced and easy to use device to prevent positional obstructive sleep apnea. The product is currently sold in 11 European countries. NightBalance’s wealth of clinical data supports the efficacy and ease of use of the device, and has demonstrated a substantial increase in patient compliance. NightBalance is based in in Delft (the Netherlands). Check out the video below this article in order to learn more about the Sleep Position Trainer.

The fresh capital will allow NightBalance to intensify and expand commercial efforts for its innovative Sleep Position Trainer in Europe, and to prepare for the company’s entry into the U.S. market. NightBalance is planning for further clinical studies in the U.S., guided by the leading sleep specialist Prof. Dr. David P. White from Harvard Medical School and former Chief Medical Officer for Philips Respironics. Also filing for U.S. Food and Drug Administration 510(k) clearance is being prepared.